← brief for 2026-09-10 · Slowing decline

Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.

Key takeaways

This is a follow-up look at 53 people from the COMET randomized trial, all with swelling in the back of the eye from diabetes. Researchers checked whether eye injections of the drug ranibizumab affected the kidneys over 48 weeks, tracking kidney filtering rate (eGFR), protein in the urine, and red blood cell levels. They also checked whether SGLT2 inhibitor drugs showed their usual kidney and blood effects in this group. The study is small and was not designed to answer this question up front, so it is a safety signal check rather than firm proof.

Who did this work

Sakai T · Ishibashi R · Koshizaka M · Takatsuna Y · Tatsumi T · Baba T · Sakurai K · Maezawa Y · Yokote K

Source

Article · PubMed, the drug frontier · 2026 Sep 9
https://pubmed.ncbi.nlm.nih.gov/42717542/